| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Chiliz Group Ltd. | 11% | $984,093 | 5,467,181 | Chiliz Group Ltd. | 05 Aug 2025 | |||
| CVI Investments, Inc. | 9% | -9% | $959,500 | +$101,502 | 5,000,000 | +12% | CVI Investments, Inc. | 30 Sep 2025 |
| INTRACOASTAL CAPITAL, LLC | 10% | 0% | $595,986 | -$22,753 | 2,907,250 | -3.7% | Mitchell P. Kopin | 30 Jun 2025 |
| ARMISTICE CAPITAL, LLC | 5% | -50% | $555,319 | +$433,812 | 2,644,376 | +357% | Armistice Capital, LLC | 30 Jun 2025 |
| 3i, LP | 4.9% | $386,847 | 1,681,944 | 3i, LP | 17 Jun 2025 |
As of 30 Sep 2025, 13 institutional investors reported holding 1,780,897 shares of Processa Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PCSA). This represents 3.2% of the company’s total 55,555,556 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 1,780,897 | $341,949 | +$267,535 | $0.19 | 13 |
| 2025 Q2 | 372,611 | $75,916 | +$30,206 | $0.20 | 12 |
| 2025 Q1 | 170,789 | $63,197 | +$10,380 | $0.37 | 9 |
| 2024 Q4 | 98,935 | $87,471 | +$44,246 | $0.88 | 8 |
| 2024 Q3 | 48,551 | $66,515 | +$4,751 | $1.37 | 8 |
| 2024 Q2 | 45,030 | $100,974 | -$146,754 | $2.24 | 8 |
| 2024 Q1 | 106,331 | $251,471 | +$251,471 | $2.36 | 9 |